Federal Home Loan Mortgage Corp (OTCMKTS:FMCC) reported that in January 2017, the total mortgage portfolio grew at an annualized pace of 3.7%. Single-family refinance-loan purchases and guarantee volume came at $20.9 billion, showing 59% of overall single-family mortgage portfolio purchase and issuances.
Relief refinance mortgages included almost 5% of single-family refinance volume in January. Total count of single-family loan changes came at 3,105. The aggregate UPB of mortgage-related investments portfolio surged by almost $0.5 billion.
Federal Home mortgage-linked securities and other mortgage-linked guarantees surged at a yearly rate of 7.4% for the reported month. The single-family SDR dropped to 0.99% in January from 1% in December. Also, multifamily delinquency rate continued to be flat at 0.03%.
The measure of exposure to changes in PMVS-L averaged $14 million. Duration gap came at 0 months. Since September 2008, the company has been working under conservatorship of the Federal Housing Finance Agency.
Federal National and Federal Home Loan investors have been on a roller-coaster ride in last couple of weeks. Both the firms have been in limbo for years as the government and the courts decide their fate. While both shares got a large boost after the election, short sellers have recorded the most gains in the past few weeks. When an appeals law made a shareholder claim challenging the legality of Freddie and Fannie ’s net-worth sweep in this month, the shares price of both firms declined more than 30%.
According to S3 Blacklight, short sellers may have booked profit of over $100 million of the news. The short Interest pointer indicates there was $205.1 million short interest in in Fannie Mae and $104.2 million short position in Freddie Mac as of last month. Annualized borrowing fees have remained between 1.5% and 2% percent so far in this year. Short sellers jumped to initiate trade into both stocks after the post-election surge.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: https://www.journaltranscript.com/disclaimer
The Next Big Thing In Biotech?https://journaltranscript.com
Get our top rated alerts on the biotech sector
Miner Stock About To Explodehttps://www.journaltranscript.com
Investors are flocking to this stock like no tomorrow !
Traders Need To Know This Nowhttps://journaltranscript.com
WallStreet is loading up on this stock. Find out why